Here are three things to know
1. The drug, Steglatro, is a SGLT2 inhibitor, which works by causing patients with Type 2 diabetes to rid glucose through their urine.
2. The oral drug enters the market as a competitor to AstraZeneca’s Farxiga, Johnson & Johnson’s Invokana and Eli Lilly and Boehringer Ingelheim’s Jardiance.
3. The FDA granted Steglatro approval as both a single-therapy or a fixed-dose combination therapy with Merck’s already-approved diabetes drug Januvia or metformin, which is an older generic version of a diabetes drug.
More articles on supply chain:
6 must-reads for supply chain leaders this week
France officials fine J&J $30M for allegedly restricting access to generic versions of its pain patch
Pfizer authorizes $10B share buyback
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
